EUCTR2012-002323-15-AT进行中（未招募）不适用
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Evaluating the Efficacy and Safety of Baricitinib (LY3009104) in Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors - RA - BEACO
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 525
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •are at least 18 years of age
- •have a diagnosis of adult-onset RA as defined by the ACR/EULAR 2010 Criteria for the Classification of RA
- •have moderately to severely active RA defined as the presence of at least 6/68 tender joints and at least 6/66 swollen joints
- •have a C-reactive protein (or hsCRP) measurement =1 times the upper limit of normal (ULN)
- •have been treated at approved doses with at least 1 biologic TNF- a inhibitor and either:
- •- experienced insufficient efficacy or loss of efficacy
- •- experienced intolerance of such treatment
- •have had regular use of at least 1 cDMARD for at least the 12 weeks prior to study entry with a continuous, nonchanging dose for at least 8 weeks prior to study entry
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •have received a biologic treatment for RA within 28 days of planned randomization
- •are currently receiving corticosteroids at doses >10 mg per day of prednisone (or equivalent) or have been receiving an unstable dosing regimen of corticosteroids within 2 weeks of study entry or within 6 weeks of planned randomization
- •have started treatment with NSAIDs or have been receiving an unstable dosing regimen of NSAIDs within 2 weeks of study entry or within 6 weeks of planned randomization
- •are currently receiving concomitant treatment with MTX, hydroxychloroquine, and sulfasalazine
- •have received any parenteral corticosteroid administered by intramuscular or intravenous (IV) injection within 2 weeks prior to study entry or within 6 weeks prior to planned randomization or are anticipated to require parenteral injection of corticosteroids during the study
- •have had 3 or more joints injected with intraarticular corticosteroids within 2 weeks prior to study entry or within 6 weeks prior to planned randomization
- •have active fibromyalgia that, in the investigator’s opinion, would make it difficult to appropriately assess RA activity for the purposes of this study
- •have a diagnosis of any systemic inflammatory condition other than RA, such as, but not limited to juvenile chronic arthritis, spondyloarthropathy, Crohn’s disease, ulcerative colitis, psoriatic arthritis, or active vasculitis
- •- Patients with secondary Sjogren’s syndrome are not excluded.
- •have a diagnosis of Felty’s syndrome
- •have had any major surgery within 8 weeks of study entry or will require major surgery during the study that, in the opinion of the investigator in consultation with Lilly or its designee, would pose an unacceptable risk to the patient
- •have experienced any of the following within 12 weeks of study entry: myocardial infarction, unstable ischemic heart disease, stroke, or have New York Heart Association stage IV heart failure
- •have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematological, neurological, or neuropsychiatric disorders or any other serious and/or unstable illness that, in the opinion of the investigator, could constitute a risk when taking investigational product or could interfere with the interpretation of data
- •are largely or wholly incapacitated permitting little or no self care, such as, being bedridden or confined to a wheelchair
- •have an eGFR based on the most recent available serum creatinine using the Modification of Diet in Renal Disease (MDRD) method of <40 mL/min/1.73 m2
- •have a history of chronic liver disease with the most recent available aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >1.5 times the ULN or the most recent available total bilirubin ?1.5 times the ULN
- •have, or have a history of, lymphoproliferative disease; or have signs or symptoms suggestive of possible lymphoproliferative disease, including lymphadenopathy or splenomegaly; or have active primary or recurrent malignant disease; or have been in remission from clinically significant malignancy for <5 years
- •have been exposed to a live vaccine within 12 weeks prior to planned randomization or are expected to need/receive a live vaccine during the course of the study (with the exception of herpes zoster vaccination)
- •have a current or recent clinically serious viral, bacterial, fungal, or parasitic infection
- •have had symptomatic herpes zoster infection within 1
研究者
相似试验
进行中（未招募）
1 期
BA058 Transdermal Phase 2 Study in Women with OsteoporosisOsteoporosis in postmenopausal womenMedDRA version: 14.1Level: PTClassification code 10031285Term: Osteoporosis postmenopausalSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2012-001921-29-DKRadius Health Inc.240
进行中（未招募）
1 期
A study to assess whether different doses of KVD824 are effective in preventing attacks of Hereditary Angiodedema Type I or Type II.EUCTR2021-000136-59-DEKalvista Pharmaceuticals Ltd48
进行中（未招募）
1 期
A Phase 3 study of investigational drug ISIS 678354 administered under skin to patients with severely increased amount of triglycerides in blood.Severe hypertryglyceridemiaMedDRA version: 20.0Level: PTClassification code 10059183Term: Familial hypertriglyceridaemiaSystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10020607Term: HyperchylomicronemiaSystem Organ Class: 100000004861EUCTR2021-002192-19-DKIonis Pharmaceuticals, Inc.540
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCA-Associated Vasculitis (AAV).EUCTR2016-001121-14-FRChemoCentryx, Inc.300
进行中（未招募）
不适用
A Controlled Study to Investigate the Effectiveness and Safety of Daily Oral TAK-875 Compared with Placebo in Individuals Diagnosed with Type 2 DiabetesType 2 diabetes mellitus (T2DM)MedDRA version: 14.1Level: LLTClassification code 10063624Term: Type II diabetes mellitus inadequate controlSystem Organ Class: 100000004861MedDRA version: 14.1Level: LLTClassification code 10029505Term: Non-insulin-dependent diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 100000004861MedDRA version: 14.1Level: LLTClassification code 10012613Term: Diabetes mellitus non-insulin-dependentSystem Organ Class: 100000004861EUCTR2011-002741-35-HUTakeda Global Research & Development Centre (Europe) Ltd.462